$1.13 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was 112.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ANTH | Exit | ANTHERA PHARMACEUTICALS INCwarrant | $0 | – | -400,000 | -100.0% | 0.00% | – |
| ITMN | Exit | INTERMUNE INC | $0 | – | -500,000 | -100.0% | -0.81% | – |
| MGLN | Exit | MAGELLAN HEALTH SVCS INC | $0 | – | -175,000 | -100.0% | -1.10% | – |
| T107PS | Exit | WRIGHT MED GROUP INC | $0 | – | -711,000 | -100.0% | -1.94% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -500,000 | -100.0% | -2.48% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -500,000 | -100.0% | -2.72% | – |
| GIVN | Exit | GIVEN IMAGING | $0 | – | -1,500,000 | -100.0% | -3.02% | – |
| MAKO | Exit | MAKO SURGICAL CORP | $0 | – | -1,200,000 | -100.0% | -3.71% | – |
| CAH | Exit | CARDINAL HEALTH INC | $0 | – | -750,000 | -100.0% | -4.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.